Reshaping the HIV treatment and prevention landscape
Cautionary statement regarding
forward-looking statements
gsk
All outlooks, targets, ambitions and expectations regarding future performance and the dividend
should be read together with the section "Basis of preparation, assumptions and cautionary
statement" on pages 5-7 of our stock exchange announcement relating to an update to
investors dated 23 June 2021 and the "Basis of preparation, assumptions and cautionary
statement" and "Reporting definitions" slides at the end of this presentation.
Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which
relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that
a number of important factors, including those in this document, could cause actual results to differ
materially from those expressed or implied in any forward-looking statement. Such factors include, but are
not limited to, those discussed under Item 3.D 'Risk Factors' in the Group's Annual Report on Form 20-F
for 2020 and any impacts of the COVID-19 pandemic.
This document contains statements that are, or may be deemed to be, "forward-looking
statements". Forward-looking statements give the Group's current expectations or forecasts of
future events. An investor can identify these statements by the fact that they do not relate strictly
to historical or current facts. They use words such as 'aim, 'ambition', 'anticipate', 'estimate',
'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar
meaning in connection with any discussion of future operating or financial performance. In
particular, these include statements relating to future actions, prospective products or product
approvals, future performance or results of current and anticipated products, sales efforts,
expenses, the outcome of contingencies such as legal proceedings, dividend payments and
financial results. Other than in accordance with its legal or regulatory obligations (including under
the Market Abuse Regulation, the UK Listing Rules and the Disclosure and Transparency Rules
of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-
looking statements, whether as a result of new information, future events or otherwise. The
reader should, however, consult any additional disclosures that the Group may make in any
documents which it publishes and/or files with the SEC. All readers, wherever located, should
take note of these disclosures. Accordingly, no assurance can be given that any particular
expectation will be met and investors are cautioned not to place undue reliance on the forward-
looking statements.
Any forward-looking statements made by or on behalf of the Group speak only as of the date they are
made and are based upon the knowledge and information available to the Directors on the date of this
presentation.
A number of Adjusted measures are used to report the performance of our business, which are non-IFRS
measures. Adjusted results, CER and other non-IFRS measures may be considered in addition to, but
not as a substitute for or superior to, information presented in accordance with IFRS. These measures are
defined and reconciliations to the nearest IFRS measure are available in our first quarter 2021 earnings
release and Annual Report on Form 20-F for FY 2020 and in the "Reporting definition" slide at the end of
this presentation. GSK provides guidance and outlooks on an Adjusted results basis only, for the reasons
set out in the "Reporting definition" slide at the end of this presentation.
2View entire presentation